Survival of esophageal cancer in China: A pooled analysis on hospital-based studies from 2000 to 2018 by Hou, Haifeng et al.
Edith Cowan University 
Research Online 
ECU Publications Post 2013 
2019 
Survival of esophageal cancer in China: A pooled analysis on 






See next page for additional authors 
Follow this and additional works at: https://ro.ecu.edu.au/ecuworkspost2013 
 Part of the Medicine and Health Sciences Commons 
Recommended Citation 
Hou, H., Meng, Z., Zhao, X., Ding, G., Sun, M., Wang, W., & Wang, Y. (2019). Survival of esophageal cancer in 
China: A pooled analysis on hospital-based studies from 2000 to 2018. DOI: https://doi.org/10.3389/
fonc.2019.00548 
10.3389/fonc.2019.00548 
Hou, H., Meng, Z., Zhao, X., Ding, G., Sun, M., Wang, W., & Wang, Y. (2019). Survival of esophageal cancer in China: A 
pooled analysis on hospital-based studies from 2000 to 2018. Frontiers in Oncology, 9, Article 548. Available here 
This Journal Article is posted at Research Online. 
https://ro.ecu.edu.au/ecuworkspost2013/6510 
Authors 
Haifeng Hou, Zixiu Meng, Xuan Zhao, Guoyong Ding, Ming Sun, Wei Wang, and Youxin Wang 
This journal article is available at Research Online: https://ro.ecu.edu.au/ecuworkspost2013/6510 
SYSTEMATIC REVIEW
published: 27 June 2019
doi: 10.3389/fonc.2019.00548














†These authors have contributed
equally to this work
Specialty section:
This article was submitted to
Cancer Epidemiology and Prevention,
a section of the journal
Frontiers in Oncology
Received: 23 February 2019
Accepted: 05 June 2019
Published: 27 June 2019
Citation:
Hou H, Meng Z, Zhao X, Ding G,
Sun M, Wang W and Wang Y (2019)
Survival of Esophageal Cancer in
China: A Pooled Analysis on
Hospital-Based Studies From 2000 to
2018. Front. Oncol. 9:548.
doi: 10.3389/fonc.2019.00548
Survival of Esophageal Cancer in
China: A Pooled Analysis on
Hospital-Based Studies From 2000 to
2018
Haifeng Hou 1*†, Zixiu Meng 1†, Xuan Zhao 1†, Guoyong Ding 1, Ming Sun 2, Wei Wang 1,3 and
Youxin Wang 2*
1 School of Public Health, Taishan Medical University, Taian, China, 2 Beijing Key Laboratory of Clinical Epidemiology, School
of Public Health, Capital Medical University, Beijing, China, 3 School of Medical and Health Sciences, Edith Cowan University,
Perth, WA, Australia
Background: Esophageal cancer (EC) causes more than 400 thousand deaths per year,
and half of them occur in China. There are discrepancies regarding the survival of EC
patients between population-based surveillance studies and hospital-based studies.
Objectives: We aimed to synthesize the survival data from hospital-based EC studies
in the Chinese population from 2000 to 2018 and to compare the survival rates between
EC patients with different clinical classifications.
Methods: The protocol of this systematic review was registered in PROSPERO
(CRD-42019121559). We searched Embase, PubMed, CNKI, and Wanfang databases
for studies published between January 1, 2000 and December 31, 2018. We calculated
the pooled survival rates and 95% confidence intervals (CIs) by Stata software (V14.0).
Results: Our literature search identified 933 studies, of which 331 studies with 79,777
EC patients met the inclusion criteria and were included in meta-analyses. The pooled
survival rates were 74.1% (95% CI: 72.6–75.7%) for 1-year survival, 49.0% (95% CI:
44.2–53.8%) for 2-years survival, 46.0% (95% CI: 42.6–49.5%) for 3-years survival,
and 40.1% (95% CI: 33.7–46.4%) for 5-years survival. An increased tendency toward
EC survival was verified from 2000 to 2018. In addition, discrepancies were observed
between EC patients with different clinical classifications (e.g., stages, histologic types,
and cancer sites).
Conclusions: Our findings showed a higher survival rate in hospital-based studies
than population-based surveillance studies. Although this hospital-based study is subject
to potential representability and publication bias, it offers insight into the prognosis of
patients with EC in China.
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INTRODUCTION
Esophageal cancer (EC) is among the top causes of cancer-
related mortality globally, resulting in more than 400 thousand
deaths each year (1). Because its incidence is increasing, EC
remains a global concern, especially in under-developed regions
(2). Annually, more than half of new cases are diagnosed in
China, where a so-called EC belt permanently exists around
Taihang Mountain (3, 4). EC ranks fifth in incidence (21.17 per
100,000), and fourth in mortality (15.58 per 100,000) among all
malignant tumors in China (5, 6). Carcinogen exposure (e.g.,
nitrosamines and their precursors, fungi, trace minerals, and
polycyclic hydrocarbons), nutritional deficiency, lifestyles, and
genetics contribute to the multistage development of EC through
(1) localized injury, (2) inflammation, (3) mutagenesis, and (4)
carcinogenesis (7, 8).
Although strategies for preventing EC are necessary, measures
to reduce morbidity or improve survival are also extremely
important. Therefore, a national screening program was
launched in 2005 in areas in China with a high prevalence
of EC, especially rural regions (9). This program includes
endoscopic examination for high-risk individuals and early
surgery in the treatment of patients with EC (5). Several
studies have reported a 50% decrease in EC deaths among
subjects served in this healthcare program (9, 10). Also, a
nationwide population-based cancer registry systemwas initiated
to collect cancer data across China in 2002 (11, 12). These
population-based survival databases enable both temporal and
spatial surveillance of the overall state of different cancers (13).
However, incomplete follow-up for registered individuals can
bias survival estimates in population-based surveillance studies.
When the registered data do not cover all eligible cancer
deaths, the survival statistics might be overestimated, particularly
for cancers with high fatality rates (14). Meanwhile, many
clinical investigations have reported the prognosis of patients
with cancer within hospitals according to clinical research
criteria. These hospital-based survival investigations can reflect
comprehensive treatment effectiveness with relatively lower loss
to follow-up than population-based studies (15). Discrepancies
exist regarding the survival of EC patients between reports
from the national cancer registry system and hospital-based
studies, as well as between hospital-based studies. The present
study aimed to systematically synthesize all eligible survival
data reported in hospital-based clinical studies in the Chinese
population in order to estimate the prognosis of hospitalized
patients with EC.
MATERIALS AND METHODS
The systematic review and meta-analyses were conducted in
accordance with the criteria of the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA) (16).
The reported PRISMA Checklist is available in the online
Table S1. As a systematic review, the protocol was registered
in PROSPERO (No. CRD-42019121559, https://www.crd.york.
ac.uk/PROSPERO/).
Literature Search Strategy
We searched Embase, PubMed, and Web of Science for
English language literature, as well as CNKI and Wanfang
for Chinese literature published between January 1, 2000 and
December 31, 2018. The combination of “China,” “Chinese,”
“survival,” “hospital,” “esophageal cancer,” “carcinoma of
esophagus,” “esophageal carcinoma,” “esophagus cancer,” “cancer
of esophagus,” “esophageal cancer,” “carcinoma of esophagus,”
“esophageal carcinoma,” “esophagus cancer,” and “cancer of
esophagus” in English or Chinese were used in the literature
search. References cited in the included articles were further
reviewed. The detailed search strategy is shown in Table S2.
Selection Criteria and Quality Assessment
First, two authors (XZ and ZM) independently reviewed the
titles and abstracts of the retrieved publications. Second, the
full text and online supplementary data were read to determine
the eligibility and quality of the literature (Table S3). Any
uncertainties and discrepancies were resolved by the third
investigator (HH) through discussion. The inclusion criteria
were (1) EC was diagnosed by pathological examination; (2) the
following data were available: number of included EC patients,
number of survived cases, or survival rates of EC patients; (3)
the survival data were obtained from hospital-based studies that
assessed the prognosis of hospitalized inpatients; (4) the ethnicity
of all EC patients was Chinese. For studies reporting on both
Chinese and other populations, only the data for the Chinese
population were included. The exclusion criteria were as follows:
(1) in vitro studies or animal studies; (2) reviews; (3) studies
that did not refer to a Chinese population; (4) studies without
survival data; (5) studies on community-based populations; (6)
low-quality studies.
Data Extraction
The following data were extracted from included studies: (1) first
author’s name, publication year, characteristics of EC patients
(e.g., age, gender, region, cancer site, clinical stage, and clinical
type), survival rate or number of survival cases, and study design.
If data of a specific population were reported in several studies
or published more than once, the most recently published or the
largest sampled study was included. Data in each subgroup (study
design, gender, regions, cancer site, clinical type, and stage) were
also extracted for subgroup analyses.
Statistical Analysis
The pooled survival rate and 95% confidence interval (CI) of
EC were calculated by Stata V14.0 (Stata Corp, College Station,
TX, USA). Cochran’s Q-test for heterogeneity, complemented
by the I2 statistic, was implemented to measure the level of
heterogeneity across original studies. A P > 0.10 and I2 < 50%
indicated no significant heterogeneity, and a fixed effect model
was utilized to calculate the pooled survival rate. Otherwise,
significant heterogeneity was assumed, then the random effect
model was carried out subsequently by the DerSimonian-
Laird method (17). Subgroup analyses on gender, cancer site,
clinical type, and stage, temporal trend, and study design were
conducted, respectively. To assess the strength and stability
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FIGURE 1 | Flow diagram of literature screening.
of pooled results, sensitivity analyses were also conducted by
successive removal of an eligible study each time. The publication
bias was estimated by funnel plot asymmetry and Begg’s adjusted
rank correlation test. A P-value < 0.05 was considered to
represent statistical significance.
RESULTS
Systematic Review and Eligible Studies
Our literature search identified 933 publications, of which 289
were fromCNKI, 451 were fromWanfang, 42 were from Embase,
58 were from PubMed, and 93 were from Web of Science.
Two authors (ZM and ZX) reviewed the retrieved literature
independently and then excluded 378 reduplicate publications.
Among the 555 publications involved in the abstract and full-
text review, 26 were not original studies, 19 were not human-
based research, 52 were not in reference to EC, seven were
not designed as hospital-based studies, 16 were not conducted
among a Chinese population, 51 were not investigations on
survival or prognosis, and 53 did not provide appropriate survival
data. Finally, 331 publications with 79,777 EC patients (52,273
males/21,874 females/5,630 unavailable; mean age 51.8 years)
that met the predefined criteria were included in our study.
The flow diagram for screening articles is shown in Figure 1.
The distributions of the studies included are shown in Figure 2
and additional details are provided in Table S4. There were 104
prospective studies and 227 retrospective studies. A total of 118
studies reported survival of patients with esophageal squamous
cell carcinoma (ESCC), eight reported survival of patients with
esophageal small cell carcinoma (SCC), two reported survival of
patients with esophageal adenocarcinoma (EAC), 119 reported
the combined data of more than one histologic type, and 84
studies did not mention the histologic classifications. Of the 331
studies, 210 were conducted in the high prevalence areas of China
(e.g., Fujian, Guangdong, Henan, Jiangsu, Shandong, Shanxi,
Shaanxi, and Sichuan provinces).
Pooled Results of EC Survival
As shown in Table 1, the observed survival rates in all eligible
studies were synthesized by a random effect model. The overall
pooled results were 74.1% (95% CI: 72.6–75.7%) for 1-year
survival, 49.0% (95% CI: 44.2–53.8%) for 2-years survival, 46.0%
(95% CI: 42.6–49.5%) for 3-years survival, and 40.1% (95% CI:
33.7–46.4%) for 5-years survival.
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FIGURE 2 | Distribution of included studies.
TABLE 1 | Pooled survival and 95% CI of esophageal cancer in low and high prevalence areas.
Survival Low prevalence areas High prevalence areas Overall
N SR (%) N SR (%) N SR (%)
1-year 115 74.1 (72.0–76.3) 117 74.2 (71.8–76.5) 232 74.1 (72.6–75.7)
2-years 62 47.6 (40.2–55.0)a 63 50.4 (45.0–55.8)a 125 49.0 (44.2–53.8)a
3-years 107 45.8 (40.2–51.5)a 104 46.2 (42.5–49.9)a 211 46.0 (42.6–49.5)a
5-years 47 41.3 (33.0–49.6)a 26 37.1 (29.3–45.0)ab 73 40.1 (33.7–46.4)a
SR, survival rate; CI, confidence interval; N, number of included studies; Between-group comparisons: aP < 0.05 compared with 1-year survival; bP < 0.05 compared with
2-years survival.
To examine the survival profiles from 2000 to 2018, we
conducted analyses on time-trend survival of patients with EC.
As shown in Figure 3 and Table S5, a tendency for increased
survival was evidenced by the pooled survival rates from 2006
to 2018. The same trends were found in both men and women
(Tables S6, S7), except that the 5-years survival rates among men
decreased from 2006 to 2015.
Subgroup analysis on study design (Figure 4 and Table S8)
indicated that the pooled survival rates in retrospective studies
were 75.3% (95%CI: 73.5–77.2%) for 1-year survival, 49.6% (95%
CI: 43.3–55.9%) for 2-years survival, 45.5% (95% CI: 41.4–49.6%)
for 3-years survival, and 39.8% (95% CI: 33.0–46.7%) for 5-years
survival. Meanwhile, the pooled survival rates in prospective
studies were 71.9% (95% CI: 68.6–75.2%) for 1-year survival,
48.1% (95% CI: 41.5–54.8%) for 2-years survival, 47.6% (95%
CI: 42.8–52.3%) for 3-years survival, and 42.6% (95% CI: 34.7–
50.4%) for 5-years survival. Moreover, subgroup analyses by sex
showed higher rates of 2-, 3-, and 5-years survival among women
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FIGURE 3 | Temporal trends of survival of esophageal cancer from 2000 to
2018. Between-group comparisons: the 1-year survival rates are significantly
higher than 2-, 3-, and 5-years survival rates between 2000 and
2018 (P < 0.05).
FIGURE 4 | Forest plot of meta-analysis of retrospective and
prospective studies.
than for those of men, while the differences were not statistically
significant (Tables S6, S7).
We also synthesized survival rates in the high prevalence areas
of China (e.g., Fujian, Guangdong, Henan, Jiangsu, Shandong,
Shanxi, Shaanxi, and Sichuan provinces), where the incidence
rates of EC are higher than other provinces. The pooled survival
rates in these high prevalence areas were 74.2% (95% CI: 71.8–
76.5%) for 1-year survival, 50.4% (95% CI: 45–55.8%) for 2-years
survival, 46.2% (95% CI: 42.5–49.9%) for 3-years survival, and
37.1% (95% CI: 29.3–45.0%) for 5-years survival (Table 1). The
prognosis of EC in high prevalence areas was similar with low
prevalence areas.
Subgroup Analyses of EC Survival by
Clinical Classifications
Thirty-five studies that involved 13,055 patients reported the
TNM stage of ED. As shown in Table 2, the pooled analyses
TABLE 2 | Pooled survival and 95% CI of esophageal cancer in different
clinical stages.
Categories Stage N SR (%)
1-year survival T1 6 95.6 (93.5–97.7)
T2 8 84.7 (79.3–90.0)a
T3 12 74.6 (68.8–80.4)a
T4 17 52.8 (39.9–65.7)abc
Overall 43 71.7 (66.5–76.9)
2-years survival T1 3 87.0 (71.0–103.0)
T2 3 51.4 (39.9–62.9)a
T3 4 34.5 (28.8–40.2)a
T4 2 11.4 (2.2–25.1)abc
Overall 12 41.8 (13.7–69.8)
3-years survival T1 10 81.0 (75.5–86.4)
T2 13 61.5 (53.6–69.3)a
T3 17 45.0 (36.9–53.1)ab
T4 11 36.3 (21.8–50.7)ab
Overall 51 53.3 (46.5–60.1)
5-years survival T1 13 75.2 (68.4–82.0)
T2 14 51.6 (43.3–59.9)a
T3 16 38.5 (30.6–46.4)a
T4 10 25.4 (14.9–36.0)ab
Overall 53 48.4 (41.6–55.1)
SR, survival rate; CI, confidence interval; N, number of included studies. Between-group
comparisons: aP < 0.05 compared with T1 group; bP < 0.05 compared with T2 group;
cP < 0.05 compared with T3 group.
showed a decreasing linear trend of survival (including 1-, 2-, 3-,
and 5-years survival) for patients with T1, T2, T3, and T4 stage
EC. A decreased trend was found in accordance with the TNM
stage classifications. The 5-years survival of patients with stage
T4 EC was 25.4% (95% CI: 14.9–36.0%), which was significantly
lower than the survival for patients with stage T1 EC (75.2%, 95%
CI: 68.4–82.0%).
The major histologic type of EC in China is ESCC, which
accounts for 90% of new cases, while adenocarcinoma is more
common in Western countries (18–20). The pooled results
(Table 3) show that the 5-years survival rate of SCC (15.5%,
95% CI: 12.4–18.6%) was significantly lower than that of ESCC
(41.7%, 95% CI: 32.4–51.0%). The 1- and 3-years survival rates of
SCC were significantly lower as well. However, only two studies
reported survival of EAC, for which the pooled 1- and 3-years
survival rates were 80.9% (95% CI: 62.3–99.5%) and 45.7 (95%
CI: 23.2–68.2%), respectively.
We performed a subgroup meta-analysis on four sites of the
original tumors. As shown in Table 4, 1-, 3-, and 5-years survival
rates were lower among patients with hypopharynx and cervical
EC than patients with thoracic EC.
Results of Publication Bias and Sensitivity
Analyses
As shown in Figure 5, the funnel plot analyses and Begg’s tests
indicated no publication bias in the meta-analyses of 3- and 5-
years survival. However, significant publication bias was detected
in both 1- and 2-years survival analyses.
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TABLE 3 | Pooled survival and 95% CI of esophageal cancer of different
histologic types.
Categories Types N SR (%)
1-year survival Combined 145 74.1 (72.1–76.0)
ESCC 80 75.3 (72.7–78.0)
SCC 5 55.6 (40.4–70.8)a
EAC 2 80.9 (62.3–99.5)
Overall 232 74.1 (72.6–75.7)
2-years survival Combined 79 50.40 (44.5–56.2)
ESCC 41 48.70 (39.9–57.6)
SCC 4 24.40 (4.6–44.2)
EAC 1 –
Overall 125 49.00 (44.2–53.8)
3-years survival Combined 127 47.8 (43.2–52.3)
ESCC 78 44.6 (39.4–49.7)
SCC 4 18.8 (2.6–35.0)a
EAC 2 45.7 (23.2–68.2)
Overall 210 46.0 (42.6–49.5)
5-years survival Combined 37 41.30 (31.7–50.9)
ESCC 31 41.70 (32.4–51.0)
SCC 4 15.50 (12.4–18.6)a
EAC 1 –
Overall 72 40.10 (33.7–46.4)
SR, survival rate; CI, confidence interval; N, number of included studies; ESCC,
esophageal squamous cell carcinoma; SCC, esophageal small cell carcinoma; EAC,
esophageal adenocarcinoma; Combined, esophageal cancer patients not classified by
histology; N, number of included original studies. Between-group comparisons: aP< 0.05
compared with ESCC group.
To address the strength and stability of the pooled results, we
conducted sensitivity analysis by omitting one study at a time.
The estimates of pooled survival were not significantly affected by
any individual study that was included in our meta-analyses (see
Figures S1–S4), indicating that our results had relative strength
and stability.
DISCUSSION
Our study examined the hospital-based survival across China of
patients with EC. Among the combined 79,777 patients from 331
hospital-based studies, the overall 5-years survival rate of EC was
40.1%. Tendency analyses show that survival rates of EC have
been increasing from 2000 to 2018. Subgroup analyses illustrate
that men with EC have poorer survival compared to women.
In China, the regions with a high prevalence of EC are
located in Fujian, Guangdong, Henan, Jiangsu, Shandong,
Shanxi, Shaanxi, and Sichuan provinces (21–25). We found
that EC survival rates in high prevalence areas were similar
to those in other regions. It is notable that 90% of ECs in
the Chinese population are ESCCs, which is inconsistent with
other ethnicities. Our study found that survival of ESCC was
significantly higher than SSC in China. As a minor histologic
type of EC in China, EAC accounts for <1% of EC (19). Among
the hundreds of studies we included, only two reported an
independent result on EAC. Due to the lack of such studies, the
TABLE 4 | The pooled survival and 95% CI of esophageal cancer at different sites.
Categories Sites N SR (%)
1-year survival Hypopharynx and cervical 6 76.5 (68.7–84.4)
Upper thoracic 15 79.3 (73.7–84.8)
Mid thoracic 19 77.6 (72.1–83.0)
Lower thoracic 15 73.3 (66.2–80.3)
Overall 55 77.1 (73.9–80.3)
2-years survival Hypopharynx and cervical 2 69.4 (45.0–93.7)
Upper thoracic 3 49.1 (25.9–72.3)
Mid thoracic 8 44.5 (35.4–53.6)
Lower thoracic 5 34.9 (6.4–63.5)
Overall 18 44.7 (36.2–53.1)
3-years survival Hypopharynx and cervical 9 40.4 (30.2–50.6)
Upper thoracic 16 48.1 (42.3–54.0)
Mid thoracic 20 44.5 (35.2–53.8)
Lower thoracic 16 46.8 (39.7–53.9)
Overall 61 45.6 (41.0–50.1)
5-years survival Hypopharynx and cervical 3 10.7 (0.1–21.4)
Upper thoracic 11 32.6 (24.8–40.4)a
Mid thoracic 12 37.4 (24.9–49.9)a
Lower thoracic 12 39.6 (31.0–48.1)a
Overall 38 35.2 (28.8–41.5)a
SR, survival rate; CI, confidence interval; N, number of included original studies. Between-
group comparisons: aP < 0.05 compared with hypopharynx group.
pooled survival of EAC might not be representative. Moreover,
TNM stage is also a crucial determinant for EC survival (26).
Our findings showed a decreased trend of survival for patients
with T1, T2, T3, and T4 stage EC. The 5-years survival rate of
patients with stage T4 EC was nearly three times lower than
that of patients with T1 EC. About half of ECs locate in the
middle thoracic esophagus, followed by lower thoracic, higher
thoracic, and hypopharyngeal parts of the esophagus (27). Our
subgroup analyses showed lower survival rates among patients
with hypopharynx and cervical EC, except for 2-years survival
rates that were obtained from two published studies. These
findings verify the relatively poorer prognosis of hypopharynx
and cervical EC.
Because China has the highest burden of EC worldwide,
our focus is to investigate the key measures of early detection
and appropriate treatment for EC patients, as well as the
strategies that can be taken to evaluate both the efficiency of
preventive policies and the effectiveness of healthcare services
across the country (28, 29). The national cancer registration
system initiated in 2002 has been reinforced since 2015 and
involved 416 population-based sites as of 2016 (30). Although
this registry provides information on nationwide epidemics and
burdens, it does not include all cancer patients in China. The
comparability and validity of the informationmight vary between
sites due to discrepancies in quality controls, as well as temporal
heterogeneities. Moreover, follow-up is not easy to implement in
the populations served by cancer registries. For instance, it has
been reported that the follow-up rate was only between 65 and
71% at some sites (31).
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FIGURE 5 | Funnel plots of publication bias analyses.
Therefore, hospital-based studies are essential in order to
predict the prognosis of patients with EC. We conducted this
systematic review to combine the hospital-based survival data of
patients with EC that were collected in accordance with clinical
research criteria. We supposed that these results presented
survival information from the viewpoint of clinical oncologists.
Our findings verified an increased tendency toward EC survival
from 2000 to 2018. The increase in EC survival has been
attributed to improved access to primary health care, greater
availability of diagnostic facilities, and improved effectiveness of
clinical treatment. The health insurance system of China has
been updated to cover all populations since 2003. Access to this
insurance support has improved the survival of patients with EC
across the country (11).
A large-scale study involving 63,506 patients with EC from 17
population-based cancer registries reported increased survival
from 20.9 to 30.3% between 2003 and 2015 (12). However,
we found a higher survival rate among the hospital-based
population. This discrepancy is because population-based
data are collected from non-inclusive study participants, while
hospital-based data come from outpatients and inpatients
who generally receive more effective therapy. Another
population-based study estimated a decrease in survival
from 19.1 to 18.1% in urban China (11), in which EC was
the only cancer with a lower survival rate in urban compared
to rural areas. Such results might be due to observation bias,
which results from loss to follow-up of EC deaths in rural areas.
In addition, it is known that in China, EC screening covered
more rural areas than urban area prior to 2012. This might lead
to the contrast fallacy between rural and urban populations.
However, we did not analyze survival in urban or rural areas
due to the lack of original information in our study. Age is
also one of the important determinants closely related to the
survival of EC. Unfortunately, we did not compare the survival
between age classifications due to the lack of original data for
age-specific groups.
In 2015, the third global surveillance of cancer survival
(CONCORD) program reported survival data from 2000 to 2014,
which included 734,428 adults with EC from 60 countries (32).
During the 15-years period, 5-years age-standardized survival
rates ranged from 10 to 30% in most countries, which was
lower than what we observed. Data from a hospital-based cancer
registry between 2002 and 2014 found that the 1-, 3-, 5-, and
10-years survival rates of EC were 55.88, 26.24, 19.62, and
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12.14%, respectively (15), which is also significantly lower than
our results.
Limitations of our study are as follows: (1) Because the
survival information is from independent studies, our findings
are not representative of survival rates in China as a whole; (2)
republication of survival data cannot be eliminated entirely; (3)
most of the data in our study are from retrospective studies
and might bias the real survival level of EC. In addition,
significant publication bias was detected in both 1- and 2-years
survival analyses. Positive publication bias indicates incomplete
acquisition of original studies and might introduce potential
fallacy to our observations.
In short, this systematic review and meta-analysis provides
hospital-based survival data for EC in China. Although this study
is subject to uncertain representability and obvious publication
bias, it offers insight into the prognosis of EC based on in-
hospital studies.
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